The European Society of Cardiology has revealed the late-breaking science sessions to be presented at the end of August.
ESC Congress 2024 will be held from the 30th August to the 2nd September at the ExCel Center in London. View the full programme here.
Clinical Trial Updates on the GLP-1 Receptor Agonist, Semaglutide
Friday 30th August, 08:15 – 09:45am
Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials – Presented by Dr Subodh Verma
Inflammation in obesity-related HFpEF: the STEP-HFpEF programme – Presented by Dr Subodh Verma
STEP-HFpEF Program Echocardiography Substudy – Presented by Dr Scott Solomon
Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease – Presented by Dr Richard Pratley
Semaglutide and cardiovascular outcomes in females with overweight and obesity: A prespecified analysis of the SELECT trial – Presented by Dr Subodh Verma
The effect of semaglutide on mortality and COVID-19-related deaths - a pre-specified analysis from the SELECT trial – Presented by Dr Benjamin Morgan Scirica
Semaglutide and cardiovascular outcomes by baseline chronic kidney disease status and albuminuria in type 2 diabetes and chronic kidney disease: results from the FLOW trial – Presented by Dr Kenneth W Mahaffey
Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials – Presented by Dr Mikhail Kosiborod
Small Trials, Trial Updates, and Other Studies on Inflammation and Immunity in Cardiovascular Disease
Friday, 30th August, 08:15 – 09:45am
Low-dose interleukin-2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY) / IVORY - Clinical Outcomes And Follow-up (IVORY FINALE) Study - Presented by Dr Rouchelle Sriranjan
Anakinra versus placebo double blind Randomized controlled trial for the treatment of Acute Myocarditis - Presented by Dr Mathieu Kerneis
Colchicine for secondary prevention of stroke and other cardiovascular events: a meta-analysis of randomised trials - Presented by Dr. Aernoud Fiolet
Cardiovascular benefit of colchicine in relation to baseline risk - Presented by Dr. N. Mohammadnia
Effect of pre-hospital pulse-dose glucocorticoid on infarct size in ST-segment elevation myocardial infarction: a randomized, blinded, placebo-controlled clinical trial - Presented by Dr. Jasmine Melissa Madsen
Randomized double-blind trial to study the benefit of Colchicine in Patients with Acutely Decompensated Heart Failure - Presented by Dr. Domingo Pascual Figal
Intravenous immunoglobulin therapy improves long-term outcome in dilated cardiomyopathy by modulating cardiac immune cell function. An update of a randomized placebo-controlled study - Presented by Dr. Stephane Heymans
Effect of short-term prednisone therapy on C-reactive protein change in emergency department patients with acute heart failure and elevated inflammatory markers - Presented by Dr. Gad Cotter
Registries, Observational, and Other Studies on TAVI
Friday, 30th August, 13:45 – 15:00pm
Long-term structural valve deterioration after TAVI: insights from the European Valve Durability TAVI registry - Presented by Dr. Cristina Giannini
Long-term benefit of isolated surgical tricuspid valve repair and replacement in patients with severe functional tricuspid regurgitation: Impact of the TRI-SCORE - Presented by Dr. Julien Dreyfus
SAVR and TAVI comparison across the Globe based on current regional registry evidence - a meta-analysis of reconstructed time-to-event data - Presented by Dr. Torsten Doenst
Aortic valve calcific volume by computed tomography angiography in patients with aortic stenosis - Presented by Dr. Jolien Geers
Serial volumetric assessment of ascending aortic dilatation in severe aortic stenosis patients who receive Transcatheter aortic valve replacement: Comparison of bicuspid and tricuspid aortic stenosis - Presented by Dr. Hyo-Soo Kim
Sex related differences in frequency, management and outcome of severe native valvular heart disease. Results from the ESC-EORP Valvular Heart Disease II survey - Presented by Dr. Julia Mascherbauer
Registries, Observational, and Other Studies on Artificial Intelligence
Friday, 30th August, 13:45 – 15:00pm
Artificial intelligence-based prediction of mortality, bleeding, and ischaemic events in cancer patients with acute coronary syndrome: A modelling study in the UK and Switzerland - Presented by Dr. Florian Wenzl
Artificial intelligence for analysis of ambulatory electrocardiography - Presented by Dr. Linda Johnson
Heart Failure detection using Artificial Intelligence for diagnostic decision support applied to echocardiography - HFDetect-AI - Presented by Dr. Geoffrey Strange
MitrAI score: machine learning models to predict mortality at 12, 24, 36 and 48 months in patients with primary and secondary mitral regurgitation treated by transcatheter edge-to-edge repair - Presented by Dr. Luigi Biasco
Machine-learning based scoring system to predict cardiogenic shock in acute coronary syndrome - Presented by Dr. Allan Bohm
Machine learning algorithm using point-of-care high-sensitivity cardiac troponin I for rapid rule-out of myocardial infarction - Presented by Dr. Betuel Toprak
Small Trials, Trial Updates, and Other Studies on Heart Failure (1)
Friday, 30th August, 16:15 – 17:15pm
The effect of dapagliflozin on accelerometer-based measures of physical activity in heart failure: an exploratory analysis of the DETERMINE trials - Presented by Dr. Kieran Docherty
Synchronized left ventricular pacing improves cardiac resynchronization therapy outcomes: insights from AdaptResponse - Presented by Dr. David Birnie
Catheter ablation in end-stage heart failure with atrial fibrillation: two-year follow-up of the CASTLE-HTx trial - Presented by Dr. Christian Sohns
A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of XXB750 in heart failure patients with reduced or mildly reduced ejection fraction - Presented by Dr. Thomas Hauser
Rapid detection of incident heart failure by artificial intelligence: lessons from the NIL-CHF trial - Presented by Dr. Simon Stewart
Highlighted Registries, Observational, and Other Studies
Saturday, 31st August, 08:15 – 09:45am
Nature-AGT: Using Causal AI to estimate the optimal timing of lowering SBP with an siRNA directed against angiotensinogen to reduce the lifetime risk of cardiovascular events - Presented by Dr. Brian A Ference
Thirty-year cardiovascular outcomes in women based on C-reactive protein, LDL cholesterol, and lipoprotein(a) - Presented by Dr. Paul M Ridker
Economic Toll of Cardiovascular Disease on Healthcare and Mortality in 50 ESC member countries - Presented by Dr. Ramon Luengo-Fernandez
Incidental and progressive tobacco smoking from childhood through young adulthood with premature structural and functional cardiac damage in 1931 children: A 14-Year Longitudinal Study - Presented by Dr. Andrew O Agbaje
Global Pretest probability study of coronary artery disease - Presented by Dr. Lohendran Baskaran Baskaran
Black carbon: a novel indicator of the risk of acute myocardial infarction associated with short-term exposure to fine particulate matter - Presented by Dr. Sunao Kojima
Incremental value of cardiac myosin binding protein C to high-sensitivity cardiac troponin for the early diagnosis of acute myocardial infarction - Presented by Dr. Pedro Lopez Ayala
Trial of switching high-sensitivity cardiac troponin assays in suspected acute coronary syndrome (TWITCH-ED) - Presented by Dr. Jasper Boeddinghaus
Small Trials, Trial Updates, and Other Studies on Heart Failure (2)
Saturday, 31st August, 08:15 – 09:45am
Thoracentesis to alleviate pleural effusion in acute heart failure: results from the pragmatic, multi-centre, open-label, randomised controlled TAP-IT trial - Presented by Dr. Signe Glargaard
Impact of a pneumococcal vaccination incentive campaign in chronic heart failure patients in France: a randomized clinical trial - Presented by Dr. Francois Roubille
Early in-hospital initiation of angiotensin-neprilysin inhibition in Japanese patients with acute heart failure: the investigator-initiated multicenter randomized PREMIER study - Presented by Dr. Atsushi Tanaka
Intensive therapeutic education strategy by specialised nurses for patients with acute Heart Failure: results from the multicentre randomized controlled EDUSTRA-HF trial - Presented by Dr. Ariel Cohen
Assessment of Digital consults in heart failure Management on clINical Impact, SafeTy and Efficiency using a RCT (ADMINISTER) trial - Presented by Dr. Mark Schuuring
Carvedilol as single maintenance therapy for Heart Failure with Improved Ejection Fraction: an open-label randomized clinical trial CATHEDRAL-HF - Presented by Dr. Deborah Belfort
WITHDRAWal of Heart Failure Pharmacotherapy in Patients with Normalized Left Ventricular Function After AF Rhythm Control in Arrhythmia Induced Cardiomyopathy-The WITHDRAW-AF Randomized Clinical Trial - Presented by Dr. Louise Segan
Assessment of non-inferiority of a hospital-at-home care pathway for patients with acute heart failure: FIL-EAS-ic - Presented by Dr. Jean-Michel Tartiere
Registries, Observational, and Other Studies on Frailty, Falls, and Sarcopenia
Saturday, 31st August, 11:00 – 12:15pm
Clinical frailty scale is independently associated with one-year mortality in a large cohort of patients with acute heart disease - Presented by Dr. Joakim Alfredsson
Relevance of frailty in patients with acute coronary syndrome - Presented by Dr. Johannes Neumann
Combining frailty into RCRI for prediction perioperative myocardial injury/infarction in patients undergoing noncardiac surgery - Presented by Dr. Linggen Gao
Impact of sarcopenia on the clinical course of older patients with peripheral artery disease - Presented by Dr. Volker H Schmitt
History of Falls is Associated with Management and Worse Prognosis in Patients with Atrial Fibrillation: An Analysis from the Prospective GLORIA-AF Registry Phase III - Presented by Dr. Giulio Francesco Romiti
Feasibility and diagnostic yield of screening for atrial fibrillation with PPG in very old and frail patients. Results from the Dutch-GERAF study - Presented by Dr. Lennaert Aris Rien Zwart
Registries, Observational, and Other Studies on Coronary Disease Including Intervention and Surgery
Saturday 31 August, 13:45 - 15:00pm
Temporal trends in the use of drug-coated balloons - Presented by Dr Rafal Januszek
Ticagrelor monotherapy or DAPT after drug-eluting coronary stenting in patients with or without acute coronary syndrome: a patient-level meta-analysis of randomized controlled trials - Presented by Dr Marco Valgimigli
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Major adverse cardiovascular events, new diagnoses, prescription redemptions and outpatient visits in patients one year after evaluation for symptoms suggestive of chronic coronary syndrome - Presented by Dr Morten Bottcher
The trajectory of functional recovery after cardiac surgery: a prospective observational cohort study - Presented by Dr Jessica Spence
Survival after PCI or CABG for multivessel disease in NSTE-ACS: a report from the SWEDEHEART registry - Presented by Dr Elmir Omerovic
Trial Updates and Other Studies on Percutaneous Coronary Intervention
Saturday, 31 August, 16:15 - 17:15pm
Clopidogrel following 1-month aspirin-free low-dose prasugrel monotherapy versus aspirin following 1-month DAPT after PCI for patients with ACS or HBR: Final 1-year results from the STOPDAPT-3 - Presented by Dr Hirotoshi Watanabe
Long-Term Outcomes with PCI Guided by Fractional Flow Reserve - Presented by Dr Carlos Collet
Titanium-nitride-oxide-coated vs drug-eluting stents in acute coronary syndromes during five-year follow-up: an individual patient data meta-analysis - Presented by Dr Thabo Mahendiran
Physiology-guided complete versus culprit-only PCI in older MI patients - Presented by Dr Simone Biscaglia
A comparison of prolonged anticoagulation versus no anticoagulation after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction - Presented by Dr Yan Yan
Small Trials, Trial Updates, and Other Studies on Hypertension
Saturday, 31 August, 5:30 PM - 6:30 PM
Renal denervation lowers all-cause and cardiovascular mortality in patients with uncontrolled arterial hypertension: a randomised, sham-controlled study – Presenter TBC
Effects of Intensive vs Standard Blood Pressure Control on Cardiovascular Outcomes in Cancer Survivors: Results from the SPRINT Randomized Trial - Presented by Dr Yichao Xiao
A machine learning algorithm for personalizing intensive blood pressure treatment: derivation from SPRINT/ACCORD-BP trials and validation in CRHCP, a pragmatic implementation trial - Presented by Dr Yingxian Sun
Long-term outcomes of intensive blood-pressure control in older patients with hypertension: final six-year results of the STEP trial - Presented by Dr Qirui Song
Fractional flow reserve to determine the appropriateness of percutaneous renal artery intervention in atherosclerotic renovascular hypertension patients: a randomized trial – Presented by Dr Jianping Li
Small Trials, Trial Updates, and Other Studies: Atrial Fibrillation Detection, Prevention and Treatment
Saturday 31st August, 5:30pm – 6:30pm
Catheter ablation in persistent atrial fibrillation: long term outcomes of the CAPLA multicentre randomised trial of pulmonary vein isolation(PVI) vs PVI plus posterior left atrial wall isolation(PWI) - Presented by Dr Peter Kistler
Randomized evaluation of decision support interventions for atrial fibrillation: Anticoagulant adherence after shared decision making interventions for stroke prevention in atrial fibrillation – Presenter TBC
Predictors and Outcomes of Atrial Fibrillation Progression in Patients with Device-Detected Subclinical AF: Insights from the ARTESiA Trial - Presented by Dr Giuseppe Boriani
Biomolecule-based prediction of sinus rhythm and interaction with early rhythm control: EAST-AFNET 4 biomolecule study - Presented by Dr Larissa Fabritz
The Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation Extend - Presented by Dr Anthony Tang
Basic and Translational Late-Breaking Science
Sunday 1st September, 08:15 – 09:45am
Gut Microbiota and Associated Metabolites Play a Key Role in the Pathogenesis of the Obesity Phenotype of Heart Failure With Preserved Ejection Fraction - Presented by Dr Rabea Asleh
Distinct cellular and molecular trajectories leading to subclinical diastolic dysfunction and the progression to HFpEF - Presented by Dr Enrique Lara-Pezzi
Different cardiovascular outcomes of vascular ageing proteomic phenogroups in normotensive and hypertensive individuals: results from the UK Biobank - Presented by Dr Matteo Lemoli
Polygenic traits and cardiac remodelling contribute to a markedly increased risk of atrial fibrillation in former elite endurance athletes - Presented by Dr Andre La Gerche
Echocardiographic screening for cardiac amyloidosis using artificial intelligence: A multi-site study for algorithm training and external validation - Presented by Dr Patricia Ann Pellikka
An isocaloric high fat diet enriched with saturated compared to polyunsaturated fat has a more detrimental effect on clinical cardiometabolic risk factors in healthy humans - Presented by Dr Nikola Srnic
The role of uremic toxin indoxyl sulfate in aggravated aortic valve stenosis under uremic conditions - Presented by Dr Philip Duesing
The individual fibrinolytic potential predicts efficacy of ultrasound-assisted catheter-directed thrombolysis in patients with acute pulmonary embolism - Presented by Dr Dominik Draxler
Small Trials, Trial Updates, and Other Studies on Coronary Artery Disease
Sunday, 1st September, 08:15 – 09:45am
Effects of Beta-Blockers on Quality of Life and Well-being in Patients with Myocardial Infarction and Preserved Left Ventricular Function - a prespecified substudy from REDUCE-AMI - Presented by Dr Robin Hofmann
Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: prespecified substudy from REDUCE-AM - Presented by Dr Philip Leissner
Coronary computed tomography angiography guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART trial - Presented by Dr Michelle Williams
Adherence to Nordic and Mediterranean dietary patterns may be associated with a lower absolute risk of incident atherosclerotic cardiovascular disease - Presented by Dr Christian Soerensen Bork
Cardiorenal effects and safety of initiation of empagliflozin after acute myocardial infarction - Presented by Dr Deepak Bhatt
Cardiovascular Risk Scoring or CT Angiography for Lifestyle and Risk Factor Modification in Primary Prevention of Cardiovascular Disease The SCOT-HEART 2 IMPACT Study - Presented by Dr Michael Mcdermott
Rehabilitation at home using mobile health in older adults after hospitalization for ischemic heart disease - Presented by Dr John Dodson
Cost-effectiveness and safety of the CADScorSystem in patients with symptoms suggestive of stable coronary artery disease - Presented by Dr Kim Wadt Skak-Hansen
Trial Updates and Other Studies in Hypertrophic Cardiomyopathy and Aortic Stenosis
Saturday 1st September, 08:15 – 09:45am
Effect of Aficamten on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM - Presented by Dr John Spertus
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Presented by Dr Sheila Hegde
Effect of Aficamten on Cardiac Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Trial - Presented by Dr Ahmad Masri
Safety and Outcomes of Standard of Care Medications Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in FOREST-HCM Trial - Presented by Dr Ahmad Masri
Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis - Presented by Dr Marko Banovic
Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: A subanalysis from the DEDICATE-DZHK6 trial - Presented by Dr Sabine Bleiziffer
Transcatheter or surgical treatment of aortic valve stenosis in patients with chronic kidney disease: an analysis from the randomized DEDICATE-DZHK 6 trial - Presented by Dr Mohamed Abdel-Wahab
Development and validation of the ASGARD-S risk score for optimal timing of echocardiograms in asymptomatic patients with non-severe aortic valve stenosis: the SEAS and SALTIRE II trials - Presented by Dr Edina Hadziselimovic
Small Trials and Other Studies on Atherosclerosis
Sunday 1st September, 11:00am – 12:00pm
Effects of Coronary Artery Calcium-Guided Statin Therapy on Atherosclerotic Progression in Intermediate-Risk People with Familial Coronary Artery Disease - Presented by Dr Nitesh Nerlekar
Functional Improvement of non-infarcT relaTed coronary artery stenosis by Extensive LDL-C Reduction with a PCSK9 Antibody - Presented by Dr Frans Berend Mensink
Treatment of periodontitis and progression of subclinical atherosclerosis: a randomized controlled clinical trial - Presented by Dr Francesco D'Aiuto
Primary Results of SLICE-CEA CardioLink-8: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Characteristics in People with Asymptomatic High-Risk Carotid Stenosis - Presented by Dr C David Mazer
Quantified characterization of atherosclerotic plaques by optical coherence tomography attenuation imaging - Presented by Dr Yun Dai Chen
Registries, Observational, and Other Studies on Lipids
Sunday 1st September, 13:45 – 15:15pm
LDL-Cholesterol levels and lipid lowering therapy in secondary prevention patients: preliminary data from BRING-UP Prevention Study - Presented by Dr Aldo Pietro Maggioni
Suboptimal Lipid Measurement and Statin Use after Percutaneous Coronary Intervention is associated with Increased Mortality: Results of a Real World Registry of 76,264 Patients in NW London - Presented by Dr Majid Akhtar
Intensive, early and sustained lowering of atherogenic lipoproteins after myocardial infarction and long-term prognosis: a nationwide cohort study of myocardial infarction patients - Presented by Dr Jessica Schubert
Association of early versus late use of combination lipid-lowering therapy with major cardiovascular outcomes after myocardial infarction: data from the SWEDEHEART registry - Presented by Dr Margret Leosdottir
A global perspective of Lp(a) levels in patients with coronary heart disease - Implications for risk factor control & future trials from the INTERASPIRE Study - Presented by Dr Kausik K Ray
Optimising oral lipid-lowering therapy regimens in high and very high-risk statin intolerant patients with dyslipidaemia: A French real-world simulation - Presented by Dr Francois Schiele
Small Trials: Cardiac Function and Remodelling
Sunday 1st September, 16:15 – 17:15pm
Strain sUrveillance during Chemotherapy for improving Cardiovascular Outcomes: Results of a Randomized Trial of Cardioprotection for Reduced Myocardial Strain (SUCCOUR-MRI) - Presented by Dr Thomas H Marwick
Catheter Ablation versus Medical Rate Control in Atrial Fibrillation with Left Ventricular Systolic Dysfunction and Myocardial Fibrosis - The CAMERA-MRI II Randomized Trial - Presented by Dr Louise Segan
Sacubitril/valsartan compared to valsartan in regressing myocardial fibrosis in stage B heart failure: the REVERSE-LVH Trial - Presented by Dr Calvin Chin
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction - Presented by Dr Jaclyn Carberry
Sacubitril/valsartan in primary prevention of cancer-therapy related cardiac dysfunction in breast cancer patients - Presented by Dr Yuling Hsu
Small Trials, Trial Updates, and Other Studies on Coronary Artery Disease and Coronary Revascularisation
Sunday 1st September, 17:30 – 18:30pm
Assessment of the microvascular resistance reserve for predicting the effect of revascularization in patients with moderate coronary stenoses - Presented by Dr Laust Dupont Rasmussen
Long-term effect of biodegradable versus durable polymer drug-eluting stents on neoatherosclerosis among STEMI patients: the international CONNECT randomized controlled intracoronary OCT trial - Presented by Dr Jonas Haener
Glycoprotein IIb/IIIa Inhibitors in patients with acute myocardial infarction and angiographic no-reflow: the randomized REVERSE-FLOW trial - Presented by Dr Ingo Eitel
Evaluation of ambulatory electrocardiographic monitoring of patients after high-risk acute coronary syndrome. A randomized trial - Presented by Dr Jose Maria De La Torre Hernandez
Small Trials and Trial Updates on Shock, Surgery, and Other Interventions
Monday 2nd September, 08:15 – 09:45am
Extracorporeal life support for acute myocardial infarction complicated by cardiogenic shock - 12 months results of the ECLS-SHOCK trial - Presented by Dr Holger Thiele
Temporary mechanical circulatory support in infarct-related cardiogenic shock - An individual patient data meta-analysis of all randomized trials with 6-month follow-up - Presented by Dr Holger Thiele
Impact of baseline surgical risk on the treatment effect of PCI and CABG in ischemic left ventricular systolic dysfunction: results of the REVIVED-BCIS2 and STICH randomized controlled trials - Presented by Dr Guillaume Marquis Gravel
Comparative Effectiveness of Percutaneous and Surgical Revascularisation in Ischaemic Left Ventricular Systolic Dysfunction: Combined Patient-Level Analysis of the REVIVED-BCIS2 and STICH Trials - Presented by Dr Matthew Ryan
Urgent surgery compared to fibrinolytic therapy for the treatment of left-sided mechanical valve thrombosis (SAFE-PVT): a randomized controlled trial - Presented by Dr Ganesan Karthikeyan
Empagliflozin for prevention of acute kidney injury in patients with type 2 diabetes mellitus undergoing extracorporeal on-pump CABG: The POST-CABGDM trial - Presented by Dr Fabio Grunspun Pitta
Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia - Presented by Dr Rodrigo Biagioni
Cardiac magnetic resonance imaging vs invasive coronary angiography as primary strategy in heart failure with reduced ejection fraction - A diagnostic randomized trial - Presented by Dr Guelmisal Gueder
Small Trials, Trial Updates, and Other Studies: Devices, Cardiac Arrest and Atrial Fibrillation Ablation
Monday 2nd September, 08:15 – 09:45am
Consistent ATP, defibrillation, and safety performance of the extravascular ICD: final results from the global EV-ICD Pivotal Study - Presented by Dr Francis D Murgatroyd
Pacing Performance of the First Leadless Pacemaker Communicating with an SICD from the full cohort of the MODULAR ATP study - Presenter TBC
Death and Neurological Outcome in Patients Delivered to a Cardiac Arrest Centre: Pre-specified secondary analyses of the ARREST Trial - Presenter TBC
Resynchronization/defibrillation for Ambulatory heart Failure Trial in patients with Permanent Atrial Fibrillation - Presented by Dr Anthony Tang
Pulsed ElectRic FiEld versus Cryoballoon to Treat Paroxysmal Atrial Fibrillation (PERFECT-PAF) Randomized Trial: a Periprocedural Clinical and Cost Analysis - Presented by Dr Gian Battista Chierchia
Using computed tomogram atrial myocardial thickness maps in cryoballoon pulmonary vein isolation: a randomized clinical trial - Presented by Dr Daehoon Kim
Conduction system pacing vs biventricular resynchronization therapy in systolic dysfunction and wide QRS: CONSYST-CRT - Presented by Dr Margarida Pujol-Lopez
Small Trials, Trial Updates, and Other Studies on Lipid Therapy
Monday 2nd September, 11:00am – 12:00pm
Cardiovascular Efficacy of Evolocumab in Patients with Obesity: Updates from FOURIER Trial - Presented by Dr Yu Mi Kang
Alternative LDL cholesterol lowering strategy vs. high-intensity statin strategy: An individual patient data meta-analysis from the randomized RACING and LODESTAR trials - Presented by Dr Myeong-Ki Hong
Apolipoprotein A-I infusions and cardiovascular outcomes in patients with acute myocardial infarction and hyperlipidemia - Presented by Dr C Michael Gibson
ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction - Presented by Dr C Michael Gibson
A randomised, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome - Presented by Dr Gerald Watts
Registries, Observational, and Other Studies on Atrial Fibrillation
Monday 2nd September, 13:45 – 15:00pm
Refining the CHA2DS2VASc risk stratification scheme: Shall we drop the Sex Category? - Presented by Dr Rui Providencia
A comparison of vascular brain lesions on magnetic resonance imaging in patients with atrial fibrillation and patients with atherosclerosis - Presented by Dr Tina Stegmann
Incidence of atrial fibrillation in cryptogenic stroke with patent foramen ovale closure: the PFO-AF study - Presented by Dr Marc Badoz
Biomarkers for improved risk prediction and biological insights in patients with atrial fibrillation - Presented by Dr Pascal Meyre
Phenotypes of pharmacological treatment in patients with atrial fibrillation: a latent class analysis from the prospective GLORIA-AF Registry Phase III - Presented by Dr Bernadette Corica
Longterm 13 Year Outcome of AF Ablation in Elderly Patients - German Ablation Registry - Presented by Dr Johannes Brachmann
Registries, Observational, and Other Studies on Cardiovascular Problems in Pregnancy
Monday 2nd September, 13:45 – 15:00pm
Bromocriptine treatment and outcome in patients with peripartum cardiomyopathy: the EORP PPCM registry - Presented by Dr Peter Van Der Meer
Pregnancy in women with prosthetic heart valves: focus on anticoagulation - Presented by Anneroos van der Zande
Prospective Pakistan registry of echocardiographic screening in asymptomatic pregnant women - Presented by Dr Sabha Bhatti
Pregnancy in women with aortic pathology or genetic predisposition for aortic disease: data from the ESC Registry of Pregnancy and Cardiac disease - Presented by Dr Jolien W Roos-Hesselink
Pregnancy outcomes in women with heart diseases: Results from the Tamil Nadu Pregnancy and Heart Disease Registry - Presented by Dr Justin Paul Gnanaraj
Artificial intelligence enabled obstetric cardiovascular screening: secondary endpoint results from the SPEC-AI Nigeria randomized clinical trial - Presented by Dr Demilade Adedinsewo
Small Trials, Trial Updates, and Other Studies on Antiplatelet and Antithrombotic Therapies
Monday 2nd September, 15:15 – 16:15pm
Long-acting Factor XI Inhibition and Periprocedural Bleeding: A Secondary Analysis from AZALEA-TIMI 71 - Presented by Dr Siddharth Patel
Aspirin and hemocompatibility related adverse events after LVAD implantation in patients with diabetes mellitus, obesity and atrial fibrillation: the ARIES-HM3 randomized clinical trial - Presented by Dr Nir Uriel
Efficacy and safety of anticoagulation in patients with device-detected atrial fibrillation by indication for acetylsalicylic acid therapy - Presented by Dr Renate B Schnabel
The Association between Age and Clinical Outcomes in Patients with Subclinical Atrial Fibrillation Treated with Apixaban: Insights from the ARTESiA Trial - Presented by Dr Marco Proietti
Changes in Cognitive Function in Patients with Subclinical Atrial Fibrillation Treated with Apixaban or Aspirin: A Sub-Study from the ARTESiA Trial - Presented by Lena Rivard
Small Trials, Trial Updates, and Other Studies on Atrial Fibrillation
Monday 2nd September, 15:15 – 16:15pm
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, the AFLOAT randomized study - Presented by Dr Gilles Montalescot
Enhanced Detection and Quickened Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial - Presented by Dr Michiel Winter
Detection of silent atrial fibrillation in high stroke risk patients using bed sensor and smartphone app: the CARE-DETECT trial - Presented by Dr Joonas Lehto
Atrial fibrillation follow-up investigation to recover memory and learning trial - Presented by Dr Xin Du
Manual chest PRESSURE during direct current cardioversion for Atrial Fibrillation: a randomized control trial (PRESSURE-AF) - Presented by Dr David Ferreira